The speed with which PSMA PET–CT has been adopted for prostate cancer imaging is unprecedented. This technique's clinical value in recurrent disease is uncontested, but its role in initial staging is unclear. Two studies now provide important data on the value of PSMA PET–CT at this management stage.
This is a preview of subscription content, log in via an institution to check access.
References
van Leeuwen, P. J. et al. Prospective evaluation of 68Gallium-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer. BJU Int. http://dx.doi.org/10.1111/bju.13540 (2016).
Rhee, H. et al. PSMA PET may improve the diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole-mount histopathology. J. Urol. http://dx.doi.org/10.1016/j.juro.2016.02.3000 (2016).
Budäus, L. et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur. Urol. 69, 393–396 (2016).
Maurer, T. et al. Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J. Urol. 195, 1436–1443 (2016).
Giesel, F. L. et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 42, 1794–1800 (2015).
Rahbar, K. et al. Correlation of intraprostatic tumor extent with 68Ga–PSMA distribution in patients with prostate cancer. J. Nucl. Med. 57, 563–567 (2016).
Zamboglou, C. et al. MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 43, 889–897 (2016).
Eiber, M. et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.12.053 (2016).
Pinaquy, J. B. et al. Comparative effectiveness of [18F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate 75, 323–331 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.A.V. is a consultant to Bayer Healthcare and Genzyme. A.P. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Verburg, F., Pfestroff, A. PSMA PET–CT in initial prostate cancer staging. Nat Rev Urol 13, 498–499 (2016). https://doi.org/10.1038/nrurol.2016.136
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.136
- Springer Nature Limited
This article is cited by
-
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies
Prostate Cancer and Prostatic Diseases (2023)
-
Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study
European Radiology (2020)
-
A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy
European Journal of Nuclear Medicine and Molecular Imaging (2017)